The loss of coverage for thousands of Arizonans reliant on the Flovent inhaler was not the result of GlaxoSmithKline discontinuing the product, but rather the result of private insurance companies declining to cover the generic alternative.
PHOENIX (CN) — GlaxoSmithKline can continue selling generic inhalers after a state judge dismissed a claim a switch from name-brand Flovent violated the Arizona Consumer Fraud Act.
Additional Reads
Read Full Article: https://www.courthousenews.com/inhaler-switch-up-not-deceptive-to-consumers-judge-finds/
